Study Shows Talactoferrin Effective for Sepsis

The study evaluated 190 patients and showed talactoferrin reduced mortality and was well-tolerated in patients with severe sepsis.

Agennix, a developer of novel therapies, has received positive results from a Phase II trial to evaluate talactoferrin, an oral immunotherapy, as a treatment for severe sepsis.

The randomised study evaluated 190 patients and showed that talactoferrin reduced mortality and was well-tolerated in patients with severe sepsis.

The Phase II trial was primarily funded by a grant from the US National Institutes of Health.

The findings from the study were presented at the 14th World Conference on Lung Cancer of the International Association for the Study of Lung Cancer in Amsterdam, the Netherlands.